Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The ACXP news feed on Stock Titan brings together company press releases, scientific updates and regulatory disclosures that highlight progress across its DNA polymerase IIIC (pol IIIC) inhibitor platform.
Readers can follow detailed announcements on ibezapolstat, Acurx’s lead oral Gram-Positive Selective Spectrum (GPSS®) antibiotic candidate for Clostridioides difficile Infection (CDI). News items include Phase 2 clinical data, preparations for international Phase 3 trials, and regulatory milestones such as FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations, EMA scientific advice, and a positive opinion from the EMA Paediatric Committee on the Pediatric Investigation Plan for ibezapolstat in children.
The ACXP news stream also covers developments in Acurx’s preclinical DNA pol IIIC pipeline, including patents granted in multiple jurisdictions for the ACX-375C program, collaborations with Leiden University Medical Center (LUMC) on structural biology of pol IIIC, and presentations at major scientific meetings like IDWeek and other infectious disease conferences. These updates often describe new data on microbiome selectivity, bile acid profiles, and potential class effects across the company’s inhibitor series.
Investors and observers can track capital markets and corporate actions reported by Acurx, such as warrant inducement transactions, equity line financings, and a 1-for-20 reverse stock split undertaken to support continued Nasdaq listing. For anyone monitoring antibiotic innovation against Gram-positive priority pathogens, the ACXP news page provides an organized view of Acurx’s clinical, regulatory, scientific and financing milestones over time.
Acurx Pharmaceuticals (NASDAQ: ACXP) presented results from the ibezapolstat Phase 2 clinical trial for C. difficile Infection (CDI) at the 17th Biennial Congress of the Anaerobe Society of the Americas. The study showed favorable gut microbiome changes, including increased Actinobacteria in treated patients. Results were consistent with earlier studies, demonstrating preservation of beneficial bacteria. Dr. Kevin Garey highlighted the robust microbiome development plan, predicting an anti-recurrence effect of ibezapolstat. The company is preparing for Phase 3 clinical trials following a successful FDA End-of-Phase 2 Meeting, with plans to expand internationally.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced the successful conclusion of an FDA End-of-Phase 2 meeting, allowing the advancement of ibezapolstat for the treatment of C. difficile Infection (CDI) to Phase 3 clinical trials. The FDA agreed on key trial elements including protocol design and patient population. The trials will involve 450 subjects using a Modified Intent-To-Treat (mITT) population. Ibezapolstat has received FDA's QIDP and Fast-Track Designation and recently obtained SME designation from the European Medicines Agency, enabling fee incentives for EU Marketing Authorization. Plans include initiating trials in the EU, UK, Japan, and Canada.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced its Q1 2024 financial and operational results, highlighting significant progress in its clinical trials and business operations.
Key achievements include positive data from the Phase 2b trial of ibezapolstat, which showed superior results over vancomycin for treating CDI, with a 94% eradication rate of C. difficile by Day 3. The FDA has agreed on the Phase 3 program and NDA filing pathway. The European Medicines Agency designated Acurx as an SME, providing fee reductions and support.
Financially, Acurx ended Q1 2024 with $8.9 million in cash, up from $7.5 million at the end of 2023. The company reported a net loss of $4.4 million, driven by increased R&D and G&A expenses. 1,121,793 shares were sold under ATM financing, raising $4.4 million.
Further data and presentations are anticipated throughout 2024 at several scientific conferences.
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.